Sigyn Therapeutics announces 1-for-40 reverse stock split

Sigyn Therapeutics announced that a 1-for-40 reverse split of its common stock will be implemented tomorrow, January 31, 2024. As a result, the Company’s common stock will trade on a post-split basis at the beginning of the trading day on January 31st under its existing trading symbol “SIGY.” The CUSIP number for the common stock following the reverse stock split will be 82674U205. The reverse stock split is intended to increase the market price per share of the Company’s common stock to gain compliance with the minimum bid listing requirement of The Nasdaq Capital Market in connection with the Company’s pending application for listing. Proportionate adjustments will be made to the conversion and exercise prices of the company’s warrants, restricted stock unit awards, stock options and to the number of shares issued and issuable under the Company’s equity incentive plans.